4T1 Cell Membrane Biomimetic Nanovehicle for Enhanced Breast Cancer Treatment.

IF 4 3区医学 Q2 CHEMISTRY, MEDICINAL ACS Medicinal Chemistry Letters Pub Date : 2024-12-16 eCollection Date: 2025-01-09 DOI:10.1021/acsmedchemlett.4c00425

Mengkang Liu, Yufeng Sun, Qiuxian Wei, Anna Zhang, SaiFei Wang, Dan Wang, Zhipeng Dong, Xiaonan Ma, Ran Yan, Yue Wang

{"title":"4T1 Cell Membrane Biomimetic Nanovehicle for Enhanced Breast Cancer Treatment.","authors":"Mengkang Liu, Yufeng Sun, Qiuxian Wei, Anna Zhang, SaiFei Wang, Dan Wang, Zhipeng Dong, Xiaonan Ma, Ran Yan, Yue Wang","doi":"10.1021/acsmedchemlett.4c00425","DOIUrl":null,"url":null,"abstract":"<p><p>In this study, hollow mesoporous silica nanoparticles (HMSN) coated with a 4T1 tumor cell membrane were used to construct biomimetic nanomaterials (DTX@CHMSN) for the treatment of breast cancer. The nanodrug can improve the water solubility of polyenetaxel (DTX) by taking advantage of the special structure, good biocompatibility, and adjustable surface chemical properties of HMSN. Hollow mesoporous silica nanoparticles are coated with 4T1 cell membranes derived from homologous tumors (CHMSN). Adhesion glycoproteins on cancer cell membranes specifically bind to receptors on the cell membranes of the same cancer cell to target specific breast cancer tissues. At the same time, the cell membrane of the 4T1 tumor also contains CD47 protein, which can be specifically recognized by the immune system to produce immune escape. Therefore, the biomimetic nanomedicine DTX@CHMSN, with homologous targeting and immune escape ability, can accumulate in large quantities at the tumor site, reduce systemic toxicity, and thus improve the therapeutic effect.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 1","pages":"51-58"},"PeriodicalIF":4.0000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726363/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsmedchemlett.4c00425","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

In this study, hollow mesoporous silica nanoparticles (HMSN) coated with a 4T1 tumor cell membrane were used to construct biomimetic nanomaterials (DTX@CHMSN) for the treatment of breast cancer. The nanodrug can improve the water solubility of polyenetaxel (DTX) by taking advantage of the special structure, good biocompatibility, and adjustable surface chemical properties of HMSN. Hollow mesoporous silica nanoparticles are coated with 4T1 cell membranes derived from homologous tumors (CHMSN). Adhesion glycoproteins on cancer cell membranes specifically bind to receptors on the cell membranes of the same cancer cell to target specific breast cancer tissues. At the same time, the cell membrane of the 4T1 tumor also contains CD47 protein, which can be specifically recognized by the immune system to produce immune escape. Therefore, the biomimetic nanomedicine DTX@CHMSN, with homologous targeting and immune escape ability, can accumulate in large quantities at the tumor site, reduce systemic toxicity, and thus improve the therapeutic effect.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

增强乳腺癌治疗的4T1细胞膜仿生纳米载体。

本研究采用4T1肿瘤细胞膜包被的中空介孔二氧化硅纳米颗粒（HMSN）构建用于治疗乳腺癌的仿生纳米材料（DTX@CHMSN）。该纳米药物利用HMSN的特殊结构、良好的生物相容性和可调节的表面化学性质，提高了多烯紫杉醇（DTX）的水溶性。中空介孔二氧化硅纳米颗粒包被来自同源肿瘤（CHMSN）的4T1细胞膜。癌细胞膜上的粘附糖蛋白特异性地与同一癌细胞细胞膜上的受体结合，以靶向特定的乳腺癌组织。同时，4T1肿瘤的细胞膜也含有CD47蛋白，可被免疫系统特异性识别，产生免疫逃逸。因此，仿生纳米药物DTX@CHMSN具有同源靶向性和免疫逃逸能力，可以在肿瘤部位大量积累，降低全身毒性，从而提高治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Medicinal Chemistry Letters CHEMISTRY, MEDICINAL-

CiteScore

7.30

自引率

2.40%

发文量

328

审稿时长

1 months

期刊介绍： ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to: Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics) Biological characterization of new molecular entities in the context of drug discovery Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc. Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic Mechanistic drug metabolism and regulation of metabolic enzyme gene expression Chemistry patents relevant to the medicinal chemistry field.

期刊最新文献

Issue Publication Information Issue Editorial Masthead In This Issue, Volume 16, Issue 12 Patent Highlights at the Frontier of Neuroscience: From Molecular Targets to Psychedelic Neurotherapeutics Development and Evaluation of 1-Hydroxypyridin-2(1H)-one Derivatives as Antibacterial Agents against Pathogenic Pseudomonas aeruginosa